Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Cash from Financing Activities (2016 - 2025)

Iovance Biotherapeutics (IOVA) has disclosed Cash from Financing Activities for 11 consecutive years, with $56.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Financing Activities rose 2332.74% to $56.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $300.8 million, a 23.01% decrease, with the full-year FY2025 number at $300.8 million, down 23.01% from a year prior.
  • Cash from Financing Activities was $56.2 million for Q4 2025 at Iovance Biotherapeutics, down from $88.1 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $258.2 million in Q1 2023 to a low of $962000.0 in Q4 2023.
  • A 3-year average of $96.2 million and a median of $72.1 million in 2025 define the central range for Cash from Financing Activities.
  • Peak YoY movement for Cash from Financing Activities: soared 14809.76% in 2024, then tumbled 91.34% in 2025.
  • Iovance Biotherapeutics' Cash from Financing Activities stood at $962000.0 in 2023, then skyrocketed by 140.02% to $2.3 million in 2024, then soared by 2332.74% to $56.2 million in 2025.
  • Per Business Quant, the three most recent readings for IOVA's Cash from Financing Activities are $56.2 million (Q4 2025), $88.1 million (Q3 2025), and $13.2 million (Q2 2025).